Approximately 70% of all BCs overexpress ERα, and these tumours are targeted with selective oestrogen receptor modulators (SERMs, such as tamoxifen or raloxifene) or compounds that reduce endogenous oestrogen production (aromatase inhibitors). Here, ESR1 is linked to neoplasm.